Delivering the Promise of Healthier Lives®

JULY 2020

OTCQB: CURR

®

© 2020 CU

RE Pharmaceutical

Forward LookingStatements

To the extent any statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. When used in this presentation the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward looking statements.

Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the company believes that the expectations reflected in the forward looking statements are reasonable, the company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our mission is to improve lives by redefining how medications are delivered and experienced.

© 2020 CU

RE Pharmaceutical

CUREPharmaceutical

We are an advanced drug delivery company that develops and manufactures innovative formulations and dosage forms:

CUREform™

We improve absorption and release of medicines and supplements into the body for easier, safer and more effective administration.

We work with companies with shared values to market and distribute pharmaceutical products and dietary supplements.

What we do How we do it

© 2020 CURE Pharmaceutical

The Problem: Oral delivery is flawed

POOR BIOAVAILABILITYFor many molecules given orally, only a fraction of the administered dose will make it to the blood due to poor solubility or degradation in the GI tract and liver.

Almost 70% of Americans are on prescription medication.1

Oral drug delivery is the most preferred route of drug administration.

NON-ADHERENCEWhen drugs don’t work well enough and cause side effects, patients stop taking them.

● 30-50% of Americans do not take medications as prescribed.2

● 40% of patients have trouble swallowing pills.3

SIDE EFFECTSWhen only a fraction of the administered dose reaches the blood, more drug needs to be given which can cause GI irritation and liver toxicities.

© 2020 CU

RE Pharmaceutical

CUREfilm®

dissolving film technologyCUREpods™

chewable pod technology

The Solution:

Advanced drug formulation and delivery platformCUREform™

CUREdrops™emulsions

*magnification: 250x

© 2020 CU

RE Pharmaceutical

CUREfilm®The Right Dosage FormDissolving film technology

Unique Attributes● Sublingual and buccal delivery options for direct

absorption into the bloodstream, avoiding first-pass metabolism

● No need for water, swallowing or chewing● Uniform drug distribution allows for precision dosing

Dose Loading● Multiple actives up to 200mg● Stable at room temperature

Applications● Suitable for both pharmaceuticals and nutraceuticals

© 2020 CU

RE Pharmaceutical

CUREdrops™The Right Dosage FormProprietary emulsion technology

Unique Attributes● Proprietary encapsulation techniques to increase

bioavailability and stability of hydrophobic or lipophilic molecules

● Versatile encapsulation that can be incorporated into different dosage forms (thin film, tincture, creams, etc.)

Dose Loading● Multiple actives up to 100mg/ml of emulsion● Stable at room temperature

Applications● Suitable for both pharmaceuticals and nutraceuticals

magnification: 250x

© 2020 CU

RE Pharmaceutical

CUREpods™The Right Dosage FormChewable pod technology

Unique Attributes● Simultaneously load fat soluble and water soluble molecules● Overcomes problems with poorly soluble and poorly

absorbed nutrients ● Multiple shapes, sizes, flavors and colors

Dose Loading● High doses of actives (grams)

Applications● Ideal for sports wellness

© 2020 CURE Pharmaceutical

CUREinside Quality

Starting in February 2020, our partners' products will bear our symbol of quality, Powered By CURE™

Powered By CURE™ signals products manufactured with our proprietary CUREform™ technology.

This quality mark highlights our commitment to high-quality products produced under strict governmental and internal quality standards.

© 2020 CU

RE Pharmaceutical

CUREform™The Right Formulation

PROTECTION FROM DEGRADATION during manufacturing, and throughout shelf

INCREASED BIOAVAILABILITY

through greater water solubility, enhanced

permeability and retention intarget tissue

BETTER PATIENT EXPERIENCE

Effective symptom relief, improved taste masking, and overall

ease of use

SPECIFIC RELEASE PROFILES

(e.g. immediate or controlled release)

© 2020 CURE Pharmaceutical

Strategic ApproachNUTRACEUTICALS

Target the growing wellness market

No FDA approval required

Faster and cheaper to launch than

pharmaceutical medicines

CUREfilm® + CUREpods™

PHARMACEUTICALSCUREfilm® + CUREdrops™

improved drug formulations for accelerated approvals via

505(b)(2) regulations with market exclusivity

CANNABINOIDSCUREfilm® + CUREdrops™ cannabinoid formulations as nutraceuticals and pharmaceuticals

encapsulation to stabilize and improve the bioavailability of cannabinoids and terpenes in oral, topical and transdermal dosage forms

DEA Schedule 1 manufacturing license to formulate and manufacture cannabinoid drugs in-house

© 2020 CU

RE Pharmaceutical

● cGMP 25,000 sq ft production plant in Oxnard, CA

● FDA-registered and audited facility ● Clean room environment● Pharmaceuticals, dietary supplements and

controlled substances (DEA schedule 1 manufacturing license)

● Expansion capability● Custom drug delivery systems developed

in a design control process

Our Capabilities

PROCESSDEVELOPMENT AND SCALE UP

cGMP MANUFACTURING FACILITY

PRODUCT DEVELOPMENT AND CHARACTERIZATION

INTELLECTUALPROPERTY

13+issued U.S. patents

21patents pending

© 2020 CU

RE Pharmaceutical

Revenue Streams

CONTRACT DEVELOPMENT AND MANUFACTURING

• Development fees• Manufacturing fees

IP LICENSING AND TECH TRANSFER

• License fees • Tech transfer fees

• Milestone payments• Royalties

IN HOUSE PRODUCT & CLINICAL DEVELOPMENT

• Upfront fees• Milestone payments

• Royalties• Manufacturing fees

© 2020 CU

RE Pharmaceutical

CUREfilm® D (weekly vitamin D3)

CUREfilm® β-Caryophyllene

Manufacturing Scale Up

Launch

CUREfilm® Sleep (two different sleep & recovery products)

Product Pipeline

CUREfilm® D (weekly vitamin D3)

CUREfilm® β-Caryophyllene

CUREfilm® Hemp

Wellness

Formulation Development

Clinical Development

Launch

CUREfilm® BLUE (Sildenafil Pre-IND)

CUREfilm® Canna (THC & CBD)

PharmaceuticalRegulatory

Filing

Formulation Development

© 2020 CU

RE Pharmaceutical

Market Opportunity

CUREfilm® Sleep

CUREfilm® Blue

CUREfilm® D

CUREfilm® β-Caryophyllene

CUREfilm®Hemp

CUREfilm® Canna

Global sales of melatonin supplements by 2024.4

Global CAGR by 2023.$2.1B 19.9% CAGR

Global sales of erectile dysfunction drugs by 2024.5

Global CAGR by 2018-2024.$7.1B 5.7% CAGR

Global sales of Vitamin D supplements by 2025.6

Global CAGR 2019-2025$1.7B 7% CAGR

Global sales of curcumin supplements by 2024.7

Global CAGR 2018-2024.$1.3B 12.3% CAGR

Global sales of cannabidiol (CBD) by 2022.8

Global CAGR 2017-2022.$1.9B 31% CAGR

Global sales medical cannabis by 2025.9

Global CAGR 2019-2025.$20.2B 24.4% CAGR

© 2020 CU

RE Pharmaceutical

●Formerly President and CEO of InnoZen Inc., CEO of Gel Tech LLC, CEO of Bio Delivery Technologies Inc.

●Lead the development of several drug delivery technologies and commercial brand extensions including Chloraseptic™, Suppress™, as well as Pediastrip™,

●B.S. degree in Biological Life Sciences; Masters Certificate in Applied Project Management , Master’s in Public Health, Masters in Wellness, Post Graduate Qualification at the University of Cambridge.

●Formerly COO of cannabis SaaS technology testing company, CEO of telehealth pharmacy and marketplace company, Managing Director at life sciences consultancy, President of N.A. Operations leading commercial initiatives for generic, specialty and branded pharmaceuticals.

●Bachelor’s degree in Economics from the University of Michigan and a Master’s in Business Administration from the New York University Stern School of Business..

JonathanBerlentChief Business Officer

●Formerly CFO, vice president and general manager positions with several venture and private equity backed companies including Inogen, Medical Analysis Systems (acquired by Thermo Fisher Scientific), CDTi Advanced Materials, and Abrisa Technologies.

●Earlier experience includes management roles with Pepsi and in public accounting.

●CPA (inactive) with a B.S., Business Administration from California Polytechnic State University, San Luis Obispo.

MikeRedardChief Financial Officer

Our Executive Team:

Robert DavidsonChief Executive Officer

© 2020 CU

RE Pharmaceutical

● Formerly Chief Accounting Officer and Controller at InnoZen, Inc.

● Auditing Manager at Green Hasson & Janks, LLP in Los Angeles.CPA and B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Mark UdellChief Accounting Officer

●Over 35 years of experience leading technical teams.

●Leadership roles in process development at Amgen Thousand Oaks and Ireland

●Management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals.

●Trained as microbiologist and chemist at Brigham Young University.

●Former VP, Strategy and Business Development with CURE Pharmaceutical

●Former Project Leader with the Boston Consulting Group focused on corporate and network strategy, operations, marketing and post-merger integration initiatives.

●PhD in Immunology from the University of Pennsylvania; BSc. in Bio-Medical sciences from Tel-Aviv University in Israel.

Vered GigiChief Scientific Officer

Our Executive Team:

Steven RuhlVice President, Manufacturing

© 2020 CU

RE Pharmaceutical

Board of Directors

William Yuan (Chairman of the Board)

●Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm.

●23 years in global finance experience.●Key strategist and advisor to international institutions. U.S.

companies include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News.

●Guided leading Asian institutions like Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp.Led Merrill Lynch Asset Management Asia,

●Managed one of the largest pension / retirement funds in the world, with a $488 billion portfolio.

●Member of the International Who’s Who of Finance, Technology, Media and Telecom.

●B.S. in Economics from Cornell University●Attended as a Mason Fellow at Harvard University’s John F.

Kennedy School.

Rob Davidson

●CEO of CURE Pharmaceutical ●Former President and CEO of InnoZen Inc., CEO of Gel Tech

LLC, CEO of Biodelivery Technologies Inc., and Director of HealthSport Inc.

●ODF expert responsible for the development of several drug delivery technologies and commercial brand extensions.

●Has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film.

●B.S., Biological Life Sciences, University of the State of New York, Excelsior College.

●Master’s Certificate, Applied Project Management , Villanova University

●Master’s, Public Health from American Military University, Virginia

●Masters in Health and Wellness from Liberty University, Virginia ●Certified Performance Enhancement Specialist and Fitness

Nutrition Specialist, National Academy of Sports Medicine●Post-Graduate Qualification, University of Cambridge.

© 2020 CU

RE Pharmaceutical

Board of Directors(continued)

John K. Bell, FCA, FCPA, ICD.D

●Served as chairman of the Canopy Rivers board of directors●Former chairman of the board of directors at Canopy Growth. ●Managing partner at Onbelay Capital Inc., a private equity and

investment firm based in Cambridge, Canada.●Member of a number of public boards, most recently with DelMar

Pharmaceuticals, which develops new treatments for cancer. ●Was the founder and CEO of Shred-Tech, Inc., a leader in the mobile

shredding industry. ●Was the owner and CEO of Polymer Technologies Inc., a global

manufacturer of auto parts. ●Served as chairman and principal shareholder of fleet management

company BSM Technologies Inc. (TSX-V) ●Former CEO and director of ATS Automation (TSX) and its 24 global

manufacturing facilities. ●A philanthropist who has contributed to and provided leadership for

numerous organizations including Cambridge Memorial Hospital, Waterloo Regional Police, Waterloo Region Prosperity Council, and Crohn’s and Colitis Canada and the Stratford festival.

Lauren Chung, Ph.D.

●Founded MINLEIGH LLC. identifying, evaluating and partnering with companies for investments and various strategic, operational, and commercial planning.

●20 years of healthcare investment management and advisory experience.

●Former Managing Director in Healthcare Research at WestPark Capital.

●Co-founder of Tokum Capital, a global healthcare fund (merged with Perella Weinberg Partners.)

●Managed healthcare investment portfolios at RBR Capital, Kingdon Capital, and Pequot Capital.

●A recognized research scientist conducting cutting edge research neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.

●Published many leading peer-reviewed scientific journals and serves as a board member in various healthcare companies.

●PhD in Neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.

© 2020 CU

RE Pharmaceutical

Anya Goldin

●28 years of experience in law, private equity, venture capital, healthcare and telecommunications industries.

●Former international business consultant ●A practicing attorney at Nolan Heimann law firm ●Co-founded Provenance Laboratories, a technology start-up. ●17 years in leadership as a managing partner at Latham & Watkins ●Served as the General Counsel, Vice President and Chair of the Risk

Management Committee of a $20-billion London Stock Exchange-listed conglomerate and served on the boards of eight public and private companies in Europe, Russia, India and the UK

●Vice Chair of the Board of Directors for a global private equity fund ●On the Advisory Board of a California private equity fund, Lumia

Capital.●On the Board of Trustees of Westmark School, and on the Board of

the LA Chapter of Berkeley Law Alumni ●A member of the State Bar of California●BA in Mass Communications from University of California Berkeley●JD from University of California Berkeley School of Law

Board of Directors(continued)

Joshua Held

●Currently the President of Form Factory Inc. a wholly owned subsidiary of Acreage Holdings (ARCG.CN) the largest multi-State cannabis operator licensed in 20 States.

●Founder and CEO of Chemistry Holdings, Inc. a formulation technology company that creates innovative, sustainable delivery systems for a variety of industries. Chemistry Holdings was recently acquired by Cure Pharmaceutical.

●CEO and founder of Made by Science (rebranded as Form Factory Inc) . a private company acquired by Acreage Holdings for $160 Million in December of 2018.

●Former Vice President of Investments for JP Morgan, managing more than $100 million in investment dollars for high-net-worth individuals and families.

●Bachelor of Arts from the California State University, Long Beach.

© 2020 CU

RE Pharmaceutical

Board of Directors(continued)

Ruben Jose King-Shaw Jr.

●C-suite positions with leading private companies including Steward Health Care System, LLC, Neighborhood Health Partnership, Inc. and JMH Health Plan.

●Former Board member, Cotiviti Holdings, Inc. and current Board member, Intelligent Retinal Imaging Systems of Pensacola, FL.

●Former Lead Director of the Board at Athenahealth; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL.

●Served on the Obama Administration's Medicare Program Advisory and Oversight Committee,

●COO and deputy administrator of the Centers for Medicare and Medicaid Services, George W. Bush administration.

●Advisor, healthcare policy to the Trump Administration.●Senior advisor to the Secretary of the U.S. Treasury, health care tax

policies. ●B.S., Industrial and Labor Relations, Cornell University, Master of

Health Service Administration and a Master of International Business, Florida International University. Advanced studies in Corporate Governance at the Harvard Business School.

Gene Salkind, MD

●Board certified in neurological surgery by the American Board of Neurological Surgery and completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veterans Administration Hospital, Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania.

●MD from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania.

●Numerous faculty, hospital and administrative appointments at virtually every major hospital in the northeastern Philadelphia and surrounding areas.

●Prolific pharmaceutical investor including Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, acquired by Johnson & Johnson for $4.9 billion in stock.

●Sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.

© 2020 CU

RE Pharmaceutical

AdvisorsMichael Willner, Esq.

●Founder of Willner Properties Services, Inc., a PA based real estate development, leasing and management company specializing in both commercial and residential properties.

●Founder of Willner Capital, Inc., a FL based investment concern that has played an activist role with several publicly traded companies.

● Investor in biotech, technology and security companies, with recent focus in cannabis related pharmaceutical companies

●Served on the Board of Directors of publicly traded Meridian Bank, served as Vice Chairman of the Board of Directors of Intervoice, Inc.

●Held positions at Milbank, Tweed, Hadley & McCloy and Arthur Andersen & Company

●Juris Doctor degree from Emory University Law School and CPA

Michael Neely, MD

●Director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years.

●Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles.

●Research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients.

●Member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology.

© 2020 CU

RE Pharmaceutical

CompanyDisclaimer

This Investor Presentation is supplied for informational purposes only and does not constitute (1) an offer to sell, or the solicitation of an offer to buy, any securities of CURE Pharmaceutical, or (2) a promise or representation that any such offer will be made to the recipient or any other party.

The offering is being made only to qualified investors. The offering shall be made pursuant to documents reasonably acceptable to the Company and the Investors, which agreements shall contain, among other things, (i) short form, basic representations and warranties by the Company, and (ii) covenants of the Company reflecting the provisions set forth herein and appropriate conditions of closing.

Documents to be drafted by counsel to the company. Read those documents before making an investment decision. The securities are being offered in reliance upon exemptions from registration under the Securities Act of 1993 and only in the states in which the offering of securities is registered or is exempt from registration and by broker-dealers authorized to do so.

© 2020 CU

RE Pharmaceutical

Credits Title page photograph: copyright © Paul Bradbury, iStock

References:

1.Zhong, Wenjun et al. Age and Sex Patterns of Drug Prescribing in a Defined American Population (2013) Mayo Clinic Proceedings, Volume 88, Issue 7, 697-707 Retrieved from: https://www.mayoclinicproceedings.org

2.Marcum, Z. et al, Medication Nonadherence: A Diagnosable and Treatable Medical Condition (2013 May 22) JAMA; 309(20): 2105–2106. doi: 10.1001/jama.2013.4638 Retrieved from: https://www.ncbi.nlm.nih.gov

3.Fields, J. et al. (2015). Pill Properties that Cause Dysphagia and Treatment Failure. Current Therapeutic Research, Clinical and Experimental, 77, 79–82. doi:10.1016/j.curtheres.2015.08.002. Retrieved from: https://www.ncbi.nlm.nih.gov

4.Industry Research, 2018-2023 Global Melatonin Consumption Market Report (2018, Aug 2) Retrieved from: https://www.industryresearch.co

5.Zion Market Research, Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024 (2018, Oct) Retrieved from: https://www.globenewswire.com

6.MarketsandMarkets Inc., Vitamin D Market by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application (Functional Food & Beverage, Pharma, Feed, and Personal Care), End User (Children, Adult, and Pregnant Women), Iu Strength and Region - Global Forecast to 2025, (2019, May) Retrieved from: https://www.marketsandmarkets.com

7.Grandview Research, Curcumin Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Food, Cosmetics), By Region (Asia Pacific, North America, CSA, Europe, MEA), And Segment Forecasts 2018 - 2025 (2018, Sep) Retrieved from: https://www.grandviewresearch.com

8.Technavio Research, Global CBD Oil Market Analysis - Size, Trends and Forecast 2018-2022), (2018, July) Retrieved from: https://www.businesswire.com

9.Market Study Report, Global Medical Cannabis Market Insights, Forecast to 2025, (2019, June) Retrieved from: https://www.marketstudyreport.com